Education
About Us
Working with TipRanks
Follow Us
Immutep Ltd (AU:IMM)
ASX:IMM
IMM Stock Chart & Stats
AU$0.26
-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.26
-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.22 - AU$0.47
Previous CloseN/A
Volume844.76K
Average Volume (3M)4.11M
Market Cap
AU$560.01M
Enterprise ValueAU$510.82M
Total Cash (Recent Filing)AU$99.13M
Total Debt (Recent Filing)AU$2.16M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Sep 02, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,473,721,300
10 Day Avg. Volume7,757,821
30 Day Avg. Volume4,106,545
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.14Price Target Upside338.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$26.61M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity PositionConservative leverage and a healthy equity base reduce refinancing and bankruptcy risk, giving management flexibility to fund R&D and clinical programs without immediate debt pressures. This structural strength supports long-term investment in trials and partnership negotiations.
Improving Free Cash Flow GrowthAn improvement in free cash flow growth indicates progress toward better cash conversion from operations. If sustained, this trend can lengthen runway, lower reliance on dilutive capital raises and improve the company's ability to fund later-stage trials or execute partnerships without urgent financing.
Proprietary LAG-3 Platform And Clinical PipelineOwning a differentiated LAG-3 research platform and an advancing clinical asset (efti) represents a durable competitive advantage: platform science can generate multiple programs, attract partnerships, and deliver long-term value if clinical and regulatory milestones are met.
Bears Say
Persistent Losses And Negative Cash FlowsSustained operating losses and negative cash flows erode financial flexibility and necessitate ongoing external funding. Over months this increases execution risk, can delay programs, and raises the probability of dilutive capital raises that impact long-term shareholder value.
Negative Margins And Operational InefficiencyBroad negative margins reflect persistent cost structures that are not yet scalable. Continued operational inefficiency increases the capital required to reach commercialization and makes the company a less attractive partner or acquirer unless efficiency or clinical value significantly improves.
Dependence On External Funding And PartnershipsAs a clinical-stage biotech without product sales, Immutep must rely on partnerships, grants and equity raises to fund development. This structural dependency creates execution and dilution risks, and program continuity hinges on securing milestone-based deals or fresh capital.
Immutep Ltd News
IMM FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest share price was AU$0.22 and its highest was AU$0.47 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is AU$560.01M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 179 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Aug 29, 2025. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of -AU$0.028 by -AU$0.002.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is -0.03.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of -AU$0.028. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in AU:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$1.14 (338.46% Upside)
AU$1.14 (338.46% Upside)
Blogger Sentiment
Bullish
AU:IMM Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-35.86%
Trailing 12-Months
Asset Growth
-23.58%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Ltd (IMM) is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and autoimmune diseases. The company specializes in the discovery and development of LAG-3 (Lymphocyte Activation Gene-3) related products, which are designed to enhance the immune response against tumors and regulate immune activity in autoimmune disorders. Immutep operates primarily within the biopharmaceutical sector, leveraging its proprietary technologies to create therapies that aim to improve patient outcomes in oncology and beyond.
IMM Stock 12 Month Forecast
Average Price Target
AU$1.14
▲(338.46% Upside)
Technical Analysis
Imugene
―
Alterity Therapeutics
―
Dimerix Limited
―
Race Oncology Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---